These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Policy coherence in US tobacco control: beyond FDA regulation. Yang JS; Novotny TE PLoS Med; 2009 May; 6(5):e1000079. PubMed ID: 19440534 [TBL] [Abstract][Full Text] [Related]
5. Considerations of Sex and Gender in FDA Tobacco Regulation. Davis DR; Krishnan-Sarin S; Mazure CM JAMA; 2023 Jun; 329(23):2017-2018. PubMed ID: 37233997 [TBL] [Abstract][Full Text] [Related]
6. Biden administration delays long-awaited ban on menthol cigarettes. Furlow B Lancet Oncol; 2024 Jun; 25(6):698-699. PubMed ID: 38705165 [No Abstract] [Full Text] [Related]
8. Tobacco control policy and regulation from diverse perspectives and contexts. Hefler M Tob Control; 2024 Mar; 33(e1):e1-e2. PubMed ID: 38503442 [No Abstract] [Full Text] [Related]
9. Protecting children from tobacco industry interference. Peters M; Vandeleur M Respirology; 2024 Jul; 29(7):542-544. PubMed ID: 38750649 [No Abstract] [Full Text] [Related]
10. The Cannabis Regulators Association Is Moving in the Right Direction, but Still Permitting Too Much Tobacco Industry Influence. Allen JA Cannabis Cannabinoid Res; 2024 Aug; 9(4):e1197-e1198. PubMed ID: 38924048 [No Abstract] [Full Text] [Related]
11. Economists are crucial for solving public health challenges. Garzon-Villalba XP Nat Med; 2024 Jan; 30(1):21. PubMed ID: 38195749 [No Abstract] [Full Text] [Related]
12. Reassessing the importance of 'lost pleasure' associated with smoking cessation: implications for social welfare and policy. Pechacek TF; Nayak P; Slovic P; Weaver SR; Huang J; Eriksen MP Tob Control; 2018 Oct; 27(e2):e143-e151. PubMed ID: 29183920 [TBL] [Abstract][Full Text] [Related]
13. Mixed methods research in tobacco control with youth and young adults: A methodological review of current strategies. Fryer CS; Seaman EL; Clark RS; Plano Clark VL PLoS One; 2017; 12(8):e0183471. PubMed ID: 28841689 [TBL] [Abstract][Full Text] [Related]
15. Consumer surplus and cost-benefit analysis of tobacco use in countries in the earlier stages of the tobacco epidemic. Ross H Tob Control; 2015 Mar; 24(2):121-2. PubMed ID: 25564286 [No Abstract] [Full Text] [Related]
16. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419 [TBL] [Abstract][Full Text] [Related]
17. FDA's toothless tiger and its "lost pleasure" analysis. Malone RE Tob Control; 2015 Mar; 24(2):105. PubMed ID: 25701876 [No Abstract] [Full Text] [Related]
19. The Deeming Rule: Keeping Pace with the Modern Tobacco Marketplace. Zeller M Am J Respir Crit Care Med; 2016 Sep; 194(5):538-40. PubMed ID: 27585382 [No Abstract] [Full Text] [Related]